Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

cnbc.com - Priyanka Salve - U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
CNBC

U.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing of generic drugs in India leads to a significant…

newswire.ca - Laminar Pharma Announces 'Last Patient, Last Visit' in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
Laminar Pharma Announces 'Last Patient, Last Visit' in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
CNW

PALMA DE MALLORCA, Spain, July 23, 2026 /CNW/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in…

thehindubusinessline.com - India pharma market enters US tariff transition with strong domestic growth: Report
India pharma market enters US tariff transition with strong domestic growth: Report
BusinessLine

India's pharmaceutical market is entering the proposed two-year transition period before the United States' planned tariffs on imported generic medicines with broad-based domestic growth momentum, according to an Equirus Securities report, which…

marketbeat.com - Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
MarketBeat

Merck, the Dow's hottest stock, gets set to report Q4 financials Shareholders of Organon & Co. NYSE: OGN approved the company's proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High - Should You Buy?
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High - Should You Buy?
MarketBeat

Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) hit a new 52-week high on Thursday. The stock traded as high as $59.44 and last traded at $59.1230, with a volume of 513102 shares traded. The stock had previously closed at $58.72. How…

marketbeat.com - Monashee Investment Management LLC Reduces Holdings in BridgeBio Pharma, Inc. $BBIO
Monashee Investment Management LLC Reduces Holdings in BridgeBio Pharma, Inc. $BBIO
MarketBeat

Monashee Investment Management LLC reduced its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 32.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The…

rediff.com - Nandita Malik - Crude Oil Prices Hit $100 Mark, Indian Stock Markets Witness Significant Decline
Crude Oil Prices Hit $100 Mark, Indian Stock Markets Witness Significant Decline
Rediff.com

Indian stock markets witnessed a sharp decline as Brent crude oil prices surged past $100 per barrel, driven by escalating geopolitical tensions in West Asia and concerns over India's Balance of Payments. Indian benchmark indices, Sensex and Nifty…

statnews.com - Elaine Chen - New data on Eli Lilly's 'triple-G' drug leave open questions on heart benefit
New data on Eli Lilly's 'triple-G' drug leave open questions on heart benefit
STAT

Eli Lilly reported more results Thursday showing that its next-generation obesity drug is highly efficacious at weight loss, but the data from the study, focused on people with heart disease, aren't enough to answer a critical question about the…

fool.com - Motley Fool Transcribing - TMO Q2 2026 Earnings Call Transcript
TMO Q2 2026 Earnings Call Transcript
The Motley Fool

Thursday, July 23, 2026 at 8:30 a.m. ET Vice President, Investor Relations - Rafael Tejada Chairman and Chief Executive Officer - Marc Casper Senior Vice President and Chief Financial Officer - Jim Meyer Need a quote from a Motley Fool analyst?

washingtonexaminer.com - Kathleen Jaeger - Tariff India, and half of America's medicine cabinet could disappear
Tariff India, and half of America's medicine cabinet could disappear
Washington Examiner

The facts tell a different story. The U.S. has built a decadeslong partnership with India, which supplies nearly half of all generic medicines that millions of Americans trust. It should not be collateral damage in broader debates about trade…

thehindu.com - Pti - Stock markets tumble in early trade as crude oil prices hit $100 per barrel mark
Stock markets tumble in early trade as crude oil prices hit $100 per barrel mark
The Hindu

Market benchmark indices Sensex and Nifty tumbled in early trade on Friday (July 24, 2026) as crude oil prices crossed $100 per barrel mark amid escalating geopolitical tensions in the West Asia. The 30-share BSE Sensex tumbled 512.07 points to…

time.com - Philip Elliott - Debate Moment Captures Democrats' Troy Jackson Jitters
Debate Moment Captures Democrats' Troy Jackson Jitters
Time

Making sense of what matters most in Washington. By signing up you are agreeing to our Terms of Service and Privacy Policy. It should have been a layup. Instead, the question illustrated why some Democrats fear they are about to swap out Graham…

tuzarapost.substack.com - Joe Tuzara, M.D. @TuzaraPost - 'Miracle Weed' Eliminated 95% of Cancer Cells in Clinical Trials with Zero Toxicity - Until Big Pharma Buried It
'Miracle Weed' Eliminated 95% of Cancer Cells in Clinical Trials with Zero Toxicity - Until Big Pharma Buried It
Tuzara Post Newsletter

A common backyard weed has shown in peer-reviewed science the power to obliterate over 95% of colon cancer cells in the lab and slash tumor growth in living organisms by more than 90%—with absolutely zero toxicity to healthy cells. So why…

seekingalpha.com - High Alpha Professor - JPMorgan: Jamie Dimon's Buyback Warning Makes 5.75% Preferred The Better Buy (JPM.PR.D)
JPMorgan: Jamie Dimon's Buyback Warning Makes 5.75% Preferred The Better Buy (JPM.PR.D)
Seeking Alpha

JPMorgan Chase & Co. common stock trades at ~3x tangible book, reflecting strong business momentum but limited upside at current valuation. I rate JPM.PR.D preferred shares a buy near $24–$24.50, offering a 6% yield, modest capital gain…

rediff.com - Nandita Malik - Cipla Q1 Net Profit Falls 39% to Rs 785.55 Cr on Weak North America Sales
Cipla Q1 Net Profit Falls 39% to Rs 785.55 Cr on Weak North America Sales
Rediff.com

Homegrown pharmaceutical giant Cipla Ltd announced a significant 39% drop in its consolidated net profit for the first quarter ended June 2026, primarily attributed to a downturn in North American sales and increased operational expenses. Cipla's…

Receive a Daily briefing on Pharma Industry News

Get Started